All practice questions

8270 questions

All types8,270 Multiple choice4,249 Multiple select325 Numeric160 Matching1,849 Ordering1,687

A 38-week-gestation male neonate is born to a 28-year-old G2P1 mother with blood type O, Rh-negative. The mother did not receive prenatal care or anti-D immune globulin during her pregnancy. At 8 hours of life, the infant becomes progressively lethargic and is noted to have significant scleral icterus and jaundice extending to the lower abdomen. A transcutaneous bilirubin measurement is markedly elevated above the 95th percentile for his age in hours. Arrange the following diagnostic and therapeutic steps in the most appropriate escalating chronological sequence for the management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct escalating sequence is: 1) Obtain confirmatory labs (serum bilirubin, DAT, reticulocyte count), 2) Initiate intensive phototherapy, 3) Administer IVIG, 4) Place umbilical vascular catheters, and 5) Perform a double-volume exchange transfusion.

The correct sequence reflects the standard algorithmic escalation of care for severe neonatal isoimmune hyperbilirubinemia. Immediate confirmatory laboratory testing is essential for any pathologic jaundice appearing in the first 24 hours of life. Intensive phototherapy is the cornerstone first-line intervention. If bilirubin levels continue to rise rapidly in the setting of confirmed immune-mediated hemolysis (such as Rh incompatibility), IVIG is administered to halt ongoing red blood cell destruction. When these temporizing measures fail and bilirubin nears the threshold for acute bilirubin encephalopathy, securing central access via umbilical catheters is urgently required to perform a definitive double-volume exchange transfusion.

Step-by-Step Solution

Recognize early-onset pathologic jaundice and obtain diagnostic laboratories.

Serum fractionated bilirubin, DAT, and reticulocyte count are drawn.

Visible jaundice presenting within the first 24 hours of life is always considered pathologic and carries a high risk of kernicterus. Serum confirmation and etiology identification (DAT for immune hemolysis) are mandatory first steps.

Initiate first-line non-invasive therapy.

Continuous intensive phototherapy is started.

Phototherapy rapidly converts neurotoxic unconjugated bilirubin into excretable isomers (lumirubin) and must be started immediately in severe cases while awaiting diagnostic lab results.

Administer targeted medical therapy for immune hemolysis.

IVIG is given.

In the setting of Rh isoimmunization, if bilirubin rises rapidly or approaches exchange transfusion thresholds despite intensive phototherapy, IVIG is administered to decrease hemolysis by blocking reticuloendothelial Fc receptors.

Prepare for definitive invasive therapy.

Umbilical venous and arterial catheters are placed.

When medical management fails to halt the bilirubin rise, central access is required to safely and effectively perform a double-volume exchange transfusion.

Execute definitive emergency therapy.

A double-volume exchange transfusion is performed.

This is the final step in the algorithmic escalation, used only when bilirubin reaches critical thresholds, directly removing circulating bilirubin and antibody-coated red blood cells to prevent permanent neurological damage.

Key Concept

The stepwise escalation of management in severe neonatal isoimmune hemolytic disease (e.g., Rh incompatibility), progressing from diagnostic confirmation to phototherapy, IVIG, and ultimately exchange transfusion.

Question 2522Question →

A 14-day-old male infant is evaluated in the neonatal intensive care unit for acute clinical deterioration. He was born at 26 weeks gestation via emergency cesarean delivery for maternal severe preeclampsia. Birth weight was 850 g (1 lb 14 oz). Apgar scores were 4 and 6 at 1 and 5 minutes, respectively. Two days ago, the infant developed feeding intolerance, abdominal distension, and grossly bloody stools. An abdominal radiograph demonstrated pneumatosis intestinalis. He was made nil per os (NPO) and started on gastric decompression, intravenous fluids, and broad-spectrum antibiotics (ampicillin, gentamicin, and metronidazole).

Over the past 2 hours, the infant has become increasingly lethargic. His temperature is 35.4°C (95.7°F), heart rate is 190/min, respiratory rate is 70/min, and blood pressure is 38/20 mmHg. He requires endotracheal intubation for escalating apneic episodes and hypoxia. Physical examination reveals a tense, rigid abdomen with marked erythema of the abdominal wall. A stat anteroposterior supine abdominal radiograph demonstrates prominent linear radiolucencies within the bowel wall and a new, large, continuous radiolucent shadow centrally that outlines the falciform ligament.

Which of the following is the most appropriate next step in the management of this patient?

Exploratory laparotomy

Continuation of current medical management and serial abdominal radiographs

Escalation of antimicrobial therapy to include intravenous vancomycin and fluconazole

Computed tomography scan of the abdomen without contrast

Reassurance and observation for a presumed transient neonatal skin eruption

Show answer & explanation

Answer: Exploratory laparotomy

Answer

Exploratory laparotomy

The correct answer is exploratory laparotomy. This premature infant initially presented with medical necrotizing enterocolitis (NEC), characterized by bloody stools and pneumatosis intestinalis. His acute deterioration, marked by septic shock (hypotension, hypothermia) and abdominal wall erythema, signals progression to severe necrotic bowel. Crucially, the new radiographic finding—a central continuous radiolucent shadow outlining the falciform ligament—is known as the 'football sign.' In a supine neonate, air rises to the anterior abdomen, and massive free air (pneumoperitoneum) outlines the falciform ligament. Pneumoperitoneum indicates a full-thickness bowel perforation, which is an absolute indication for immediate surgical intervention (exploratory laparotomy or primary peritoneal drainage).

Step-by-Step Solution

Identify the primary diagnosis based on the initial presentation.

The history of prematurity, feeding intolerance, bloody stools, and pneumatosis intestinalis confirms a baseline diagnosis of necrotizing enterocolitis (NEC).

Establishing the underlying pathophysiology is necessary to contextualize the patient's acute deterioration.

Analyze the acute clinical changes and vital signs.

The infant has developed hypothermia, severe hypotension, tachycardia, and respiratory failure requiring intubation, indicating the onset of septic shock.

Hemodynamic instability strongly suggests disease progression and failure of the initial medical management.

Interpret the physical exam findings and the repeat abdominal radiograph.

Abdominal wall erythema suggests severely necrotic bowel. The distinct radiolucent outline of the falciform ligament (the 'football sign') is diagnostic of massive pneumoperitoneum.

Accurate interpretation of this specific imaging sign establishes the presence of a full-thickness bowel perforation.

Determine the appropriate management protocol.

Bowel perforation in the setting of NEC is an absolute indication for immediate surgical intervention.

Medical management cannot treat a free intestinal perforation; surgical source control via laparotomy (or primary peritoneal drainage) is required to prevent death.

Key Concept

Surgical indications in Neonatal Necrotizing Enterocolitis (NEC)

Question 2523Question →

A 24-year-old female undergoes comprehensive coagulation testing for a lifelong history of mucocutaneous bleeding and menorrhagia. Her hematologist suspects a variant of von Willebrand disease (vWD) and orders a full diagnostic panel, including vWF antigen (vWF:Ag), vWF ristocetin cofactor activity (vWF:RCo), Factor VIII activity, ristocetin-induced platelet aggregation (RIPA), and multimer analysis. Match the specific laboratory profiles below with their exact underlying molecular pathophysiology.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The laboratory profiles map to vWD subtypes as follows: enhanced RIPA/thrombocytopenia matches the gain-of-function glycoprotein Ib binding (Type 2B); isolated low Factor VIII matches impaired carrier binding (Type 2N); proportionate decrease matches partial quantitative deficiency (Type 1); and decreased RIPA matches ADAMTS13 susceptibility/assembly defect (Type 2A).

Precise classification of von Willebrand disease subtypes is critical because their management differs drastically. For example, administering desmopressin (DDAVP) is a standard treatment for Type 1, but it is contraindicated in Type 2B because it can exacerbate spontaneous platelet agglutination and worsen thrombocytopenia. The distinct laboratory findings provided in the stem directly reflect the underlying molecular pathophysiology for each subtype, allowing for definitive matching.

Step-by-Step Solution

Identify the quantitative variant (proportionate decrease, ratio > 0.7).

Matches the partial quantitative deficiency of functionally normal vWF (Type 1).

In Type 1 vWD, the defect affects the amount of vWF, not its structure or function, preserving the ratio.

Isolate the variant mimicking Hemophilia A (low Factor VIII, normal vWF parameters).

Matches the mutation impairing vWF's carrier binding affinity (Type 2N).

vWF acts as a protective carrier protein for Factor VIII. When this binding site is defective, Factor VIII is rapidly degraded in the plasma.

Distinguish between the two variants with absent large multimers (ratio < 0.7). Evaluate the profile with markedly decreased RIPA and a normal platelet count.

Matches the mutation rendering vWF susceptible to ADAMTS13 cleavage or impairing assembly (Type 2A).

Without large multimers, normal platelet agglutination fails, resulting in decreased RIPA.

Evaluate the remaining multimer-deficient profile showing enhanced RIPA at low-dose ristocetin and mild thrombocytopenia.

Matches the gain-of-function mutation causing excessive spontaneous binding to glycoprotein Ib (Type 2B).

The hyperactive vWF spontaneously binds platelets in vivo, clearing large multimers and platelets from circulation, which explains both the enhanced in vitro aggregation to minimal ristocetin and the in vivo thrombocytopenia.

Key Concept

Pathophysiology and advanced laboratory differentiation of von Willebrand Disease (vWD) subtypes

Alternative Method

When evaluating vWD panels, always look at the vWF:RCo to vWF:Ag ratio first. If > 0.7, it is a quantitative defect (Type 1 or 3). If < 0.7, it is a qualitative defect (Type 2A, 2B, or 2M). From there, use RIPA and multimer analysis to differentiate the Type 2 variants.

Estimated Time:3m 0s

Question 2524Question →

A 54-year-old woman is brought to the emergency department by her husband due to a severe headache, blurry vision, and worsening shortness of breath over the past 48 hours. She was diagnosed with diffuse cutaneous systemic sclerosis 3 years ago. Her current medications include mycophenolate mofetil, low-dose prednisone, and omeprazole. Her temperature is 37.0°C (98.6°F), blood pressure is 226/118 mm Hg, pulse is 112/min, and respirations are 26/min. Oxygen saturation is 91% on room air. Physical examination reveals thickened, tethered skin over her face, chest, and proximal extremities. Cardiopulmonary auscultation reveals a prominent S4 gallop and bilateral basilar crackles.

Laboratory results are as follows:

Parameter	Value	Reference Range
Hemoglobin	$9.1 \text{ g/dL}$	$12.0-16.0 \text{ g/dL}$
Platelet count	$98,000/\text{mm}^3$	$150,000-400,000/\text{mm}^3$
Serum creatinine	$3.6 \text{ mg/dL}$ (Baseline: $0.9 \text{ mg/dL}$ )	$0.6-1.2 \text{ mg/dL}$
Blood urea nitrogen	$52 \text{ mg/dL}$	$7-18 \text{ mg/dL}$
Serum sodium	$136 \text{ mEq/L}$	$136-145 \text{ mEq/L}$
Serum potassium	$4.8 \text{ mEq/L}$	$3.5-5.0 \text{ mEq/L}$
Serum chloride	$104 \text{ mEq/L}$	$98-106 \text{ mEq/L}$
Serum bicarbonate	$14 \text{ mEq/L}$	$22-28 \text{ mEq/L}$
Arterial blood gas (room air)	$\text{pH } 7.31, p\text{CO}_2 \text{ } 29 \text{ mm Hg}, p\text{O}_2 \text{ } 62 \text{ mm Hg}$
Serum TSH	$0.9 \text{ } \mu\text{U/mL}$	$0.5-5.0 \text{ } \mu\text{U/mL}$
Serum free T4	$0.6 \text{ ng/dL}$	$0.9-1.7 \text{ ng/dL}$

A peripheral blood smear demonstrates 4 to 5 schistocytes per high-power field.

Which of the following is the most appropriate next step in the management of this patient?

Initiate therapy with captopril

Administer intravenous furosemide and noninvasive positive-pressure ventilation

Administer empiric broad-spectrum intravenous antibiotics

Administer an intravenous sodium bicarbonate infusion

Initiate therapy with oral levothyroxine

Show answer & explanation

Answer: Initiate therapy with captopril

Answer

The most appropriate next step is to initiate therapy with captopril.

The correct approach is to initiate therapy with captopril. This patient is presenting with scleroderma renal crisis (SRC), a life-threatening complication of diffuse cutaneous systemic sclerosis. SRC is characterized by the sudden onset of malignant hypertension, acute kidney injury (AKI), and microangiopathic hemolytic anemia (evidenced by schistocytes and thrombocytopenia on the peripheral smear). The underlying pathophysiology involves acute renal vascular injury leading to ischemia and massive, unchecked activation of the renin-angiotensin-aldosterone system (RAAS). Therefore, rapid RAAS blockade with a short-acting angiotensin-converting enzyme (ACE) inhibitor, such as captopril, is the definitive treatment. Paradoxically, while ACE inhibitors are generally withheld in patients with AKI due to the risk of worsening renal perfusion, they are the standard of care for SRC and are the only medications proven to improve mortality and preserve long-term renal function in this condition.

Step-by-Step Solution

Identify the primary acute syndrome based on the clinical presentation and laboratory findings.

The patient exhibits malignant hypertension, acute kidney injury (AKI), and microangiopathic hemolytic anemia (schistocytes, thrombocytopenia) in the context of diffuse cutaneous systemic sclerosis.

These findings form the classic clinical triad for scleroderma renal crisis (SRC).

Determine the underlying pathophysiology driving the syndrome.

SRC is caused by acute renal vascular intimal proliferation and ischemia, leading to massive, unchecked activation of the renin-angiotensin-aldosterone system (RAAS).

Understanding the RAAS-driven mechanism is essential for selecting the targeted pharmacotherapy to halt the process.

Select the optimal pharmacological intervention to interrupt the disease progression.

A short-acting angiotensin-converting enzyme (ACE) inhibitor, such as captopril, must be administered immediately.

Although ACE inhibitors are typically contraindicated in the setting of acute kidney injury, they are uniquely life-saving in SRC and are the only class of medication proven to restore renal function and prevent mortality in this specific crisis.

Key Concept

Scleroderma renal crisis presents with acute malignant hypertension, acute kidney injury, and microangiopathic hemolytic anemia; it must be treated immediately with an ACE inhibitor (e.g., captopril), even in the setting of acute kidney injury.

Question 2525Question →

During routine morning rounds, a pediatrician evaluates a 48-hour-old female infant. The parents are highly anxious because they noticed multiple "red blotches with white centers" appearing on their daughter's trunk and thighs earlier this morning. The infant was born at 39 weeks of gestation via uncomplicated spontaneous vaginal delivery. Vital signs are within normal limits, and the infant is actively breastfeeding. Physical examination reveals widely scattered erythematous macules, several of which contain 1- to 2-mm central pale-yellow pustules. The infant's palms and soles are completely unaffected. Which of the following is the most appropriate next step in management?

Observation and routine newborn care

Administration of intravenous acyclovir

Initiation of intravenous ampicillin and gentamicin

Application of topical mupirocin

Isolation of the infant and contact precautions

Show answer & explanation

Answer: Observation and routine newborn care

Answer

Observation and routine newborn care

The infant's presentation of scattered erythematous macules with central yellowish pustules, notably sparing the palms and soles in an otherwise healthy term newborn, is the classic description of erythema toxicum neonatorum (ETN). ETN is a benign, self-limited rash that typically appears within the first few days of life. No diagnostic testing or treatment is required, and management consists of reassuring the parents and providing routine newborn care.

Step-by-Step Solution

Identify the key clinical features of the rash from the vignette.

The rash consists of erythematous macules with central yellow pustules, appearing at 48 hours of life, sparing palms and soles in a well-appearing, healthy infant.

Accurate characterization of the rash is essential to differentiate benign neonatal skin conditions from serious infectious etiologies.

Formulate a diagnosis based on the clinical presentation.

The findings are pathognomonic for erythema toxicum neonatorum (ETN).

ETN is a highly common, benign rash seen in healthy term newborns during the first few days of life.

Determine the appropriate management for this specific diagnosis.

No medical intervention or diagnostic testing is needed. Observation and routine care are indicated.

ETN is entirely self-resolving and requires only parental reassurance.

Key Concept

Recognition and management of erythema toxicum neonatorum, a benign, self-limited rash in healthy newborns that requires no intervention.

Estimated Time:1m 0s

Question 2526Question →

A $65$ -year-old man is evaluated in the hospital for new-onset right lower extremity swelling and pain. He underwent a complex open cholecystectomy and lysis of adhesions $7$ days ago. His postoperative course was complicated by a superficial wound infection, which is currently being treated with targeted antibiotic therapy. Since the day of surgery, he has been receiving subcutaneous unfractionated heparin for deep venous thrombosis prophylaxis.

Vital signs include a temperature of $37.2^\circ\text{C}$ ( $99.0^\circ\text{F}$ ), heart rate of $92/\text{min}$ , and blood pressure of $130/80\text{ mm Hg}$ . Physical examination reveals a swollen, erythematous, and tender right calf.

Laboratory studies show the following:

Test	Result
Hemoglobin	$11.2 \text{ g/dL}$
Leukocyte count	$8,500/\mu\text{L}$
Platelet count	$95,000/\mu\text{L}$
Preoperative platelet count	$220,000/\mu\text{L}$
Creatinine	$1.1 \text{ mg/dL}$

Lower extremity venous duplex ultrasonography reveals a noncompressible right popliteal vein.

Which of the following is the most appropriate next step in management?

Discontinue unfractionated heparin and start argatroban

Discontinue unfractionated heparin and start enoxaparin

Discontinue unfractionated heparin and start warfarin

Continue unfractionated heparin and start a therapeutic-dose continuous infusion

Administer pooled platelets and discontinue unfractionated heparin

Show answer & explanation

Answer: Discontinue unfractionated heparin and start argatroban

Answer

The most appropriate next step in management is to discontinue unfractionated heparin and start argatroban.

The correct action is to discontinue unfractionated heparin and initiate a direct thrombin inhibitor (e.g., argatroban). This patient has classic Type 2 Heparin-Induced Thrombocytopenia (HIT), defined by a fall in platelet count of

>50\%

occurring

5

10

days after heparin initiation, alongside a new thrombotic event (popliteal DVT). Pathophysiologically, IgG antibodies form against the heparin-platelet factor 4 (PF4) complex. These immune complexes bind to platelet surfaces, causing widespread platelet activation, consumption (leading to thrombocytopenia), and massive thrombin generation (leading to arterial and venous thrombosis). The absolute priority is to halt the immune trigger by stopping all heparin exposure and to provide immediate therapeutic anticoagulation using an alternative non-heparin agent (e.g., argatroban, bivalirudin, fondaparinux) to manage the profound prothrombotic state.

Step-by-Step Solution

Analyze the timeline and laboratory values.

The patient experienced a

>50\%

decrease in his platelet count (from

220,000/\mu\text{L}

95,000/\mu\text{L}

) over

7

days while exposed to unfractionated heparin.

Identifying the temporal relationship between heparin exposure (

5

10

days) and significant thrombocytopenia (

>50\%

drop) is required to clinically suspect Heparin-Induced Thrombocytopenia (HIT).

Correlate laboratory findings with the clinical presentation.

The patient presents with a new right popliteal deep venous thrombosis (DVT) concurrently with the thrombocytopenia.

HIT is a highly prothrombotic state (Type 2 HIT). The presence of a new arterial or venous thrombosis confirms the severe clinical consequence of the antibody-mediated platelet activation.

Determine the immediate therapeutic intervention.

All heparin products must be stopped immediately, and a non-heparin anticoagulant must be initiated to treat the acute thrombosis.

Continuing heparin fuels the underlying pathophysiology, while an alternative fast-acting anticoagulant (like argatroban) is essential to prevent extension of the DVT and fatal complications like pulmonary embolism.

Key Concept

Patients who develop a >50% drop in platelets or new thrombosis 5-10 days after heparin exposure likely have Heparin-Induced Thrombocytopenia (HIT). Management requires immediate cessation of all heparin products (including LMWH) and initiation of a non-heparin anticoagulant like argatroban, bivalirudin, or fondaparinux.

Estimated Time:1m 30s

Question 2527Question →

A 65-year-old man comes to the office due to sudden, severe pain and swelling in his right big toe that began early this morning. He reports that the pain is so intense he cannot tolerate a bedsheet touching the foot. His medical history includes hypertension, diet-controlled type 2 diabetes mellitus, and stage 4 chronic kidney disease with a baseline serum creatinine of 2.8 mg/dL. His medications include amlodipine and bumetanide. Vital signs are within normal limits. Examination of the right foot shows a swollen, warm, dusky red, and exquisitely tender first metatarsophalangeal joint. Arthrocentesis yields cloudy yellow synovial fluid. Analysis of the fluid demonstrates a leukocyte count of 35,000/mm³ with 85% neutrophils. Polarized light microscopy reveals numerous needle-shaped crystals with strong negative birefringence. Which of the following is the most appropriate treatment for this patient's current condition?

Intra-articular triamcinolone

Oral indomethacin

Oral colchicine

Oral allopurinol

Intravenous vancomycin

Show answer & explanation

Answer: Intra-articular triamcinolone

Answer

Intra-articular triamcinolone

The correct answer provides localized, potent anti-inflammatory action without systemic toxicity. This patient is experiencing an acute gout flare, confirmed by the presence of needle-shaped, negatively birefringent crystals (monosodium urate) in the synovial fluid. The standard first-line therapies for acute gout include NSAIDs, colchicine, and systemic or intra-articular glucocorticoids. However, this patient has stage 4 chronic kidney disease. NSAIDs are strongly contraindicated as they can cause acute kidney injury. Colchicine requires extreme caution and dose adjustment in severe renal impairment, making it a less favorable choice. Systemic glucocorticoids could be used but may worsen glycemic control in his diabetes. An intra-articular injection of a glucocorticoid (such as triamcinolone) is highly effective for monoarticular flares and provides excellent localized relief while minimizing systemic absorption and renal risks.

Step-by-Step Solution

Diagnose the underlying condition based on clinical and laboratory findings.

The patient has an acute gout flare, evidenced by podagra (first metatarsophalangeal joint involvement) and synovial fluid showing negatively birefringent needle-shaped crystals.

Accurate diagnosis is required before initiating targeted therapy.

Evaluate the patient's comorbidities that affect pharmacologic management.

The patient has stage 4 chronic kidney disease (creatinine 2.8 mg/dL) and diabetes mellitus.

Comorbidities heavily dictate the safety profile of acute gout therapies.

Select the most appropriate treatment option avoiding contraindicated medications.

Intra-articular glucocorticoids (like triamcinolone) are chosen because NSAIDs and colchicine are contraindicated or highly risky in advanced renal failure.

Localized therapy resolves the acute inflammation effectively without exacerbating underlying renal dysfunction or causing systemic metabolic derangements.

Key Concept

Management of acute gout flares in patients with severe renal impairment requires avoiding NSAIDs and colchicine; intra-articular or systemic glucocorticoids are the preferred therapies.

Question 2528Question →

An 18-month-old boy is brought to the pediatrician for a well-child visit and vaccination update. He was diagnosed with minimal change disease one month ago and has been taking oral prednisone at a dose of 2 mg/kg/day since the diagnosis. His parents report that he is doing well overall and his edema has resolved. They are concerned about his development, noting that while he can walk backward, scribble with crayons, and use about 15 individual words, he cannot yet jump with both feet or use two-word phrases. The patient missed his 12-month and 15-month appointments and has not received any immunizations since 6 months of age. Vital signs are within normal limits. Physical examination reveals a playful child with a cushingoid appearance but no peripheral edema. Which of the following is the most appropriate management regarding his immunizations and development?

Administer age-appropriate inactivated vaccines, defer live-attenuated vaccines, and reassure the parents regarding his development

Administer all age-appropriate routine vaccines and reassure the parents regarding his development

Administer age-appropriate inactivated vaccines, defer live-attenuated vaccines, and refer for a developmental evaluation

Administer all age-appropriate routine vaccines and refer for a developmental evaluation

Defer all immunizations until the corticosteroid therapy is completed and reassure the parents regarding his development

Show answer & explanation

Answer: Administer age-appropriate inactivated vaccines, defer live-attenuated vaccines, and reassure the parents regarding his development

Answer

Administer age-appropriate inactivated vaccines, defer live-attenuated vaccines, and reassure the parents regarding his development

The correct management is to administer inactivated vaccines, defer live-attenuated vaccines, and reassure the parents. This patient is receiving high-dose systemic corticosteroids (defined as ≥2 mg/kg/day or ≥20 mg/day of prednisone or its equivalent for 14 or more consecutive days). This level of therapy induces profound immunosuppression. Consequently, live-attenuated vaccines (such as MMR and Varicella, which he missed at 12 and 15 months) are strictly contraindicated due to the risk of uncontrolled vaccine-strain infection, and must be deferred until at least one month after steroid discontinuation. However, inactivated vaccines (such as DTaP, IPV, Hib, PCV15, and HepA) are entirely safe for immunocompromised patients and should be administered immediately to provide critical protection. Developmentally, the child is perfectly on track for an 18-month-old: he can walk backwards, scribble, and has a typical vocabulary of about 15 words. His parents' concerns involve milestones expected at 24 months (jumping with both feet, two-word phrases), so reassurance is the only developmental intervention required.

Step-by-Step Solution

Evaluate the patient's medication list for contraindications to immunizations.

The patient is on high-dose systemic corticosteroids (2 mg/kg/day for 4 weeks), which causes significant immunosuppression.

Immunosuppression dictates which vaccines can be safely administered.

Determine the appropriate vaccine administration plan based on immune status.

Live-attenuated vaccines (e.g., MMR, varicella) must be deferred, while inactivated vaccines (e.g., DTaP, Hib, PCV, HepA) are safe and should be given to catch the patient up.

Live vaccines carry a risk of vaccine-strain disseminated infection in immunocompromised hosts, but inactivated vaccines carry no such risk.

Assess the patient's developmental milestones against standardized age expectations.

Walking backward, scribbling, and a 15-word vocabulary are normal for 18 months. Jumping and two-word phrases are 24-month milestones.

Accurate milestone tracking prevents unnecessary referrals and provides appropriate parental reassurance.

Key Concept

Live vaccines are contraindicated in patients on high-dose corticosteroids, but inactivated vaccines should be given; 18-month milestones include walking backwards, 10-25 words, and scribbling.

Question 2529Question →

A 68-year-old man with a history of prostate cancer presents to the emergency department with progressively worsening lower back pain for the past two weeks. Today, he developed profound weakness in both legs and has been unable to urinate for the past 12 hours. Physical examination reveals motor strength of $3/5$ in the bilateral lower extremities, decreased pinprick sensation below the umbilicus, and hyperreflexia at the knees and ankles. The bladder is palpable above the pubic symphysis. Arrange the following management steps in the most appropriate chronological order for this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first administer high-dose intravenous glucocorticoids, followed by performing an urgent MRI of the entire spine. After the diagnosis is confirmed by imaging, a neurosurgical or radiation oncology consultation should be obtained to plan and then initiate definitive decompressive therapy.

The patient's presentation of progressive back pain, lower extremity weakness, sensory level deficit, and urinary retention in the setting of known prostate cancer is highly suspicious for malignant epidural spinal cord compression. The absolute first step in management is the immediate administration of high-dose intravenous glucocorticoids (e.g., dexamethasone) to reduce peritumoral edema and prevent irreversible neurologic injury. This must be done immediately. Once steroids are given, an urgent MRI of the entire spine is performed to confirm the diagnosis and delineate the extent of the disease. Following imaging confirmation, urgent consultation with neurosurgery or radiation oncology is obtained to plan definitive therapy (surgery or radiation), which is then executed as the final acute step.

Step-by-Step Solution

Administer high-dose intravenous glucocorticoids

Rapid reduction of vasogenic edema surrounding the spinal cord.

Immediate preservation of neurologic function is the highest priority upon clinical suspicion, and this sight- or limb-saving therapy must not be delayed for imaging.

Perform urgent magnetic resonance imaging (MRI) of the entire spine

Visualization of the spinal cord and surrounding structures.

Confirms the diagnosis, locates the exact level of compression, and identifies any subclinical secondary lesions, which is required for definitive treatment planning.

Obtain urgent neurosurgical or radiation oncology consultation

Expert evaluation of imaging and patient clinical status.

Necessary to decide between surgical decompression versus radiation therapy based on tumor type, spinal stability, and patient operative risk.

Initiate definitive surgical decompression or targeted radiation therapy

Relief of mechanical pressure on the spinal cord.

Provides long-term preservation of neurologic function, prevents further deterioration, and assists with pain control.

Key Concept

In suspected malignant epidural spinal cord compression, high-dose intravenous corticosteroids must be administered immediately upon clinical suspicion, prior to obtaining confirmatory neuroimaging.

Estimated Time:1m 30s

Question 2530Question →

Match each classic pediatric infectious disease clinical presentation with its correct causative pathogen.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The presentations map respectively to: Parvovirus B19, Human herpesvirus 6 (HHV-6), Coxsackievirus A, and Streptococcus pyogenes.

Each pediatric exanthem has a highly characteristic clinical presentation that allows for clinical diagnosis without the need for extensive laboratory testing. Parvovirus B19 causes the 'slapped cheek' rash (Erythema infectiosum); HHV-6 causes a rash that appears only after the fever breaks (Roseola); Coxsackievirus A causes vesicular lesions on the hands, feet, and oral mucosa (Hand-foot-and-mouth disease); and Streptococcus pyogenes causes a distinct sandpaper-like rash with pharyngitis (Scarlet fever).

Step-by-Step Solution

Analyze the first clinical presentation: 'slapped cheek' appearance followed by a lacy, reticular rash.

This is the classic description of Erythema infectiosum (Fifth disease).

Recognizing classic exanthem patterns is essential for identifying the causative viral agent, which in this case is Parvovirus B19.

Evaluate the second presentation: high fever for 3 days followed by a rash strictly after the fever resolves.

This sequence defines Roseola infantum (Sixth disease).

The timing of the rash relative to the fever is the key diagnostic feature for Roseola, caused by Human herpesvirus 6 (HHV-6).

Assess the third presentation: oral ulcers combined with a vesicular rash on palms and soles.

This anatomic distribution is pathognomonic for Hand-foot-and-mouth disease.

Coxsackievirus A is the primary etiology for Hand-foot-and-mouth disease in children.

Review the fourth presentation: exudative pharyngitis accompanied by a 'sandpaper-like' rash and circumoral pallor.

This combination of symptoms is diagnostic of Scarlet fever.

Scarlet fever is a delayed-type hypersensitivity reaction to an erythrogenic exotoxin produced by Streptococcus pyogenes.

Key Concept

Classic presentations of pediatric exanthems and their causative viral or bacterial pathogens.

Estimated Time:1m 0s

Question 2531Question →

Match each pediatric patient's clinical presentation with the most likely causative viral pathogen.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The presentations map as follows: the truncal rash after abrupt defervescence matches Human herpesvirus 6; the cephalocaudal rash with postauricular lymphadenopathy matches Rubella virus; the slapped cheek and reticular extremity rash matches Parvovirus B19; and the vesicular lesions on palms, soles, and mucosa matches Coxsackievirus A.

Each vignette describes a distinct, high-yield pediatric viral exanthem. The high fever ending abruptly with a truncal rash is the hallmark of roseola infantum (Human herpesvirus 6). Postauricular lymphadenopathy with a downward-spreading rash is characteristic of rubella (Rubella virus). The 'slapped cheeks' appearance with a reticular extremity rash defines erythema infectiosum (Parvovirus B19). Finally, vesicles on the oral mucosa, palms, and soles perfectly indicate hand-foot-and-mouth disease (Coxsackievirus A).

Step-by-Step Solution

Analyze the chronology of fever and rash morphology in each clinical vignette.

The distinct morphological and chronological patterns indicate Roseola infantum, Rubella, Erythema infectiosum, and Hand-foot-and-mouth disease.

Accurate pattern recognition of pediatric exanthems is essential for differentiating these closely related viral syndromes.

Associate each identified clinical syndrome with its classic viral etiology.

Roseola links to HHV-6, Rubella links to Rubella virus, Erythema infectiosum links to Parvovirus B19, and Hand-foot-and-mouth disease links to Coxsackievirus A.

Each classic exanthem has a specific, highly tested viral pathogen.

Key Concept

Clinical presentation and etiology of classic pediatric viral exanthems

Question 2532Question →

A 15-month-old boy is brought to the clinic for a routine well-child examination. Three months ago, he was hospitalized for 5 days with a persistent high fever, bilateral bulbar conjunctival injection, cracked erythematous lips, and a diffuse maculopapular rash. During that admission, he was successfully treated with a single dose of intravenous immunoglobulin (IVIG, $2 \text{ g/kg}$ ) and high-dose aspirin. An echocardiogram performed at the time was normal. He was discharged on low-dose aspirin, which was discontinued last week following a normal follow-up echocardiogram. His last immunizations were administered at his 6-month well-child visit. His temperature is 37.1°C (98.8°F), heart rate is 105/min, and blood pressure is 85/50 mm Hg. Physical examination today shows a well-appearing, active toddler with no abnormalities. The parents are requesting that he receive all vaccines he is currently eligible for to catch up on his schedule. Which of the following is the most appropriate recommendation regarding this patient's immunizations today?

Administer age-appropriate inactivated vaccines today and defer live-attenuated vaccines for 8 more months

Administer all age-appropriate inactivated and live-attenuated vaccines today

Administer age-appropriate inactivated vaccines and the measles-mumps-rubella (MMR) vaccine today; defer the varicella vaccine

Defer all immunizations today and schedule a return visit in 8 more months for full catch-up vaccination

Administer all age-appropriate vaccines today and schedule an additional dose of live-attenuated vaccines in 8 months

Show answer & explanation

Answer: Administer age-appropriate inactivated vaccines today and defer live-attenuated vaccines for 8 more months

Answer

Administer age-appropriate inactivated vaccines today and defer live-attenuated vaccines for 8 more months.

The patient's history of prolonged fever, conjunctivitis, cracked lips, and rash treated with IVIG establishes a diagnosis of Kawasaki disease. Intravenous immunoglobulin (IVIG) consists of pooled IgG antibodies that provide passive immunity but concurrently interfere with the body's ability to mount an immune response to live-attenuated viral vaccines (e.g., MMR, varicella). Because live vaccines require viral replication within the host to produce adequate immunity, circulating exogenous antibodies can neutralize the vaccine viruses, rendering the immunization ineffective. The necessary deferral period depends on the dose of IVIG administered; the high dose used for Kawasaki disease (

2 \text{ g/kg}

) requires a strict 11-month deferral. Since the patient received IVIG 3 months ago, live-attenuated vaccines must be deferred for an additional 8 months. Conversely, inactivated vaccines (e.g., DTaP, Hib, PCV, HepB, IPV) do not require replication and their immunogenicity is unaffected by IVIG. They should be administered today to keep the child properly protected and on schedule.

Step-by-Step Solution

Diagnose the patient's past illness based on the clinical history provided.

The patient had Kawasaki disease (fever, conjunctivitis, mucositis, rash) treated with high-dose IVIG (

2 \text{ g/kg}

Identifying the disease and its specific treatment is required to anticipate any interference with routine preventive care.

Determine the interaction between the patient's past treatment (IVIG) and his required 15-month immunizations.

IVIG contains pooled IgG antibodies that neutralize live-attenuated vaccines (like MMR and varicella) but do not affect the immune response to inactivated vaccines.

Understanding which vaccine types are affected dictates which vaccines can be safely and effectively given today.

Calculate the required deferral time for the affected vaccines.

High-dose IVIG (

2 \text{ g/kg}

) requires an 11-month deferral of live vaccines. Because 3 months have passed since the treatment, the live vaccines must be deferred for an additional 8 months.

Passive immunity degrades over time; an 11-month interval ensures exogenous antibodies fall below the threshold that interferes with vaccine virus replication.

Key Concept

Live-attenuated vaccine deferral following intravenous immunoglobulin (IVIG) administration

Question 2533Question →

A middle-aged patient with stage 3 chronic kidney disease is evaluated for a maximally swollen, erythematous, and exquisitely tender first metatarsophalangeal joint. This marks the third similar episode within the past twelve months. Previous synovial fluid analysis definitively identified negatively birefringent, needle-shaped crystals. The attending physician outlines a comprehensive pharmacological protocol aimed at resolving the current symptoms and eventually depleting the total body urate pool. Arrange the following therapeutic steps in the correct chronological sequence, from immediate acute management to long-term maintenance.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: 1) Administer an oral glucocorticoid taper, 2) Initiate a xanthine oxidase inhibitor with anti-inflammatory prophylaxis, 3) Titrate the medication to achieve a serum uric acid

< 6.0

mg/dL, and 4) Cease the prophylactic agent after months of target maintenance.

The correct sequence reflects the standard stepwise approach to chronic gout management in patients with renal impairment. Acute inflammation is first controlled with renal-safe agents (glucocorticoids). Subsequently, urate-lowering therapy is initiated alongside prophylaxis to prevent mobilization flares. The urate-lowering therapy is then actively titrated to a specific biochemical target. Finally, once clinical stability is achieved, prophylaxis is withdrawn to minimize long-term medication burden.

Step-by-Step Solution

Control the acute flare with a renal-safe agent (oral glucocorticoids).

Complete resolution of acute joint inflammation and pain.

Acute flares must be resolved prior to focusing on long-term management. Glucocorticoids are preferred over NSAIDs or full-dose colchicine in patients with stage 3 chronic kidney disease.

Start a xanthine oxidase inhibitor (e.g., allopurinol) with concurrent low-dose prophylaxis.

Reduction of systemic urate production while preventing acute mobilization flares.

Rapid decreases in serum urate can precipitate paradoxical attacks; thus, low-dose prophylaxis (e.g., prednisone or adjusted-dose colchicine) is required when initiating urate-lowering therapy.

Titrate the xanthine oxidase inhibitor dose based on laboratory monitoring.

Serum urate decreases to the therapeutic target of

< 6.0

mg/dL.

Fixed-dose urate-lowering therapy is often insufficient; a treat-to-target approach is necessary to gradually dissolve existing monosodium urate crystal deposits.

Discontinue the prophylactic agent while continuing the xanthine oxidase inhibitor.

Patient remains on lifelong urate-lowering monotherapy without unnecessary drug toxicity.

Once the target urate level is sustained for 3 to 6 months without subsequent flares, the risk of mobilization flares drops significantly, rendering prophylaxis unnecessary.

Key Concept

The sequential pharmacological management of gout requires resolving the acute flare with comorbidity-appropriate agents, initiating treat-to-target urate-lowering therapy with concurrent prophylaxis, and eventually withdrawing prophylaxis once the urate target is durably maintained.

Estimated Time:1m 30s

Question 2534Question →

A 42-year-old man is hospitalized for community-acquired pneumonia. On admission, he presented with a temperature of 38.9°C (102.0°F), a productive cough, and a right lower lobe infiltrate on chest radiograph. He was empirically started on intravenous ceftriaxone and azithromycin. On hospital day 3, his temperature is 37.1°C (98.8°F), blood pressure is 122/78 mm Hg, pulse is 78/min, and oxygen saturation is 97% on room air. He is tolerating a regular diet and states he is feeling much better. Sputum cultures collected on admission have grown Streptococcus pneumoniae. Susceptibility testing shows the isolate is sensitive to penicillin, amoxicillin, ceftriaxone, levofloxacin, and vancomycin. Which of the following is the most appropriate next step in management?

Discontinue current antibiotics and start oral amoxicillin

Continue intravenous ceftriaxone and azithromycin

Discontinue current antibiotics and start oral levofloxacin

Discontinue current antibiotics and start oral amoxicillin-clavulanate

Discontinue current antibiotics and start intravenous ampicillin

Show answer & explanation

Answer: Discontinue current antibiotics and start oral amoxicillin

Answer

Discontinue current antibiotics and start oral amoxicillin

The patient has demonstrated significant clinical improvement, is hemodynamically stable, and is tolerating an oral diet. These factors make him an ideal candidate for intravenous-to-oral antibiotic transition. The sputum culture definitively identified Streptococcus pneumoniae that is sensitive to penicillin and amoxicillin. According to core principles of antimicrobial stewardship, empiric broad-spectrum therapy should be narrowed to the most targeted, effective agent available once susceptibility data returns. Oral amoxicillin provides excellent coverage for susceptible S. pneumoniae without inducing unnecessary broad-spectrum selection pressure.

Step-by-Step Solution

Evaluate the patient's clinical trajectory and stability on hospital day 3.

The patient is afebrile, hemodynamically stable, maintaining normal oxygen saturation on room air, and tolerating an oral diet.

Establishing clinical stability is the primary requirement for safely transitioning a patient from intravenous to oral antibiotics.

Analyze the sputum culture and susceptibility results to guide targeted therapy.

The identified pathogen is Streptococcus pneumoniae, which testing confirms is susceptible to narrow-spectrum beta-lactams including penicillin and amoxicillin.

Culture data allows clinicians to de-escalate from broad-spectrum empiric therapy to a targeted regimen, minimizing collateral damage to normal flora.

Select the most appropriate definitive therapeutic agent.

Oral amoxicillin is chosen to complete the treatment course.

It offers highly effective, targeted therapy against the susceptible isolate and facilitates safe hospital discharge.

Key Concept

Antibiotic stewardship principles dictate transitioning from broad-spectrum intravenous therapy to targeted, narrow-spectrum oral therapy once clinical stability is achieved and culture susceptibilities are known.

Estimated Time:1m 0s

Question 2535Question →

Emergency medical services bring an unresponsive 21-year-old university student to the emergency department. Her roommate reports she had been complaining of a severe headache, nausea, and photophobia for the past 24 hours. Vital signs show a temperature of 39.2°C (102.5°F), blood pressure of 90/60 mmHg, heart rate of 115/min, and respiratory rate of 22/min. Physical examination reveals marked nuchal rigidity and a diffuse non-blanching petechial rash on her lower extremities. Fundoscopic examination demonstrates bilateral papilledema.

Arrange the following diagnostic and therapeutic steps in the most appropriate chronological sequence for this patient's management.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The most appropriate chronological sequence is: 1) Obtain blood cultures, 2) Administer empiric antibiotics and dexamethasone, 3) Perform a CT scan of the head, 4) Perform a lumbar puncture.

This patient presents with a classic presentation of meningitis (fever, nuchal rigidity, altered mental status) and a petechial rash highly suspicious for meningococcemia. Due to the presence of papilledema and unresponsiveness, there is a high risk of brain herniation if a lumbar puncture is performed immediately. Therefore, a CT scan of the head is required prior to the procedure. However, initiating antimicrobial therapy is a medical emergency and must not be delayed while waiting for imaging. The correct sequence is to first draw blood cultures to maximize diagnostic yield, immediately administer empiric antibiotics (ceftriaxone, vancomycin) and dexamethasone, then proceed with the CT scan, and finally perform the lumbar puncture once mass effect has been ruled out.

Step-by-Step Solution

Draw peripheral blood cultures

Secures blood samples for microbiological testing.

Must be done first to guide targeted therapy, taking care not to significantly delay life-saving antibiotic administration.

Administer empiric antibiotics and dexamethasone

Provides immediate treatment for suspected bacterial meningitis.

Because the patient has papilledema and altered mental status, an immediate lumbar puncture is contraindicated. Antibiotics must never be delayed for neuroimaging in suspected bacterial meningitis.

Perform a non-contrast CT scan of the head

Evaluates for intracranial mass lesions, midline shift, or severe cerebral edema.

Required before a lumbar puncture in this patient due to signs of increased intracranial pressure (papilledema, altered mental status) to prevent brainstem herniation.

Perform a lumbar puncture

Obtains cerebrospinal fluid for cell count, chemistry, Gram stain, and culture.

Once the CT scan confirms the absence of mass effect, the lumbar puncture can be safely performed to definitively diagnose the central nervous system infection.

Key Concept

In patients with suspected bacterial meningitis who have indications for a CT scan before lumbar puncture (e.g., papilledema, altered mental status, focal neurologic deficits), blood cultures should be drawn immediately, followed by empiric antibiotics and corticosteroids, prior to sending the patient for the CT scan.

Estimated Time:1m 30s

Question 2536Question →

A $21$ -year-old woman is brought to the emergency department by her college roommate due to sudden-onset confusion, agitation, and rapid breathing. The roommate reports that the patient has been highly stressed studying for final examinations and recently complained of a continuous ringing sensation in her ears. The patient has no known past medical history and takes no medications. Her temperature is $37.9^\circ\text{C}$ ( $100.2^\circ\text{F}$ ), blood pressure is $112/70 \text{ mm Hg}$ , pulse is $118/\text{min}$ , and respirations are $32/\text{min}$ . Physical examination reveals a diaphoretic, anxious woman with deep, rapid breaths. There are no focal neurologic deficits.

Laboratory studies show the following:

Test	Result
Serum sodium	$140 \text{ mEq/L}$
Serum potassium	$3.6 \text{ mEq/L}$
Serum chloride	$104 \text{ mEq/L}$
Serum bicarbonate	$12 \text{ mEq/L}$
Blood urea nitrogen	$16 \text{ mg/dL}$
Serum creatinine	$1.0 \text{ mg/dL}$
Blood glucose	$95 \text{ mg/dL}$

Arterial blood gas on room air:

Test	Result
pH	$7.44$
$\text{PaCO}_2$	$18 \text{ mm Hg}$
$\text{PaO}_2$	$98 \text{ mm Hg}$

Which of the following is the most appropriate next step in management?

Intravenous sodium bicarbonate

Endotracheal intubation

Intravenous regular insulin and normal saline

Intravenous ceftriaxone and vancomycin

Intravenous furosemide and noninvasive positive pressure ventilation

Show answer & explanation

Answer: Intravenous sodium bicarbonate

Answer

Intravenous sodium bicarbonate is the correct management.

The patient's presentation of tinnitus, tachypnea, fever, and confusion, combined with a mixed high anion gap metabolic acidosis and primary respiratory alkalosis, is classic for acute salicylate toxicity. Salicylates directly stimulate the medullary respiratory center (causing a primary respiratory alkalosis) and uncouple oxidative phosphorylation (causing an accumulation of organic acids and a primary high anion gap metabolic acidosis). The most appropriate next step in management is the administration of intravenous sodium bicarbonate. This alkalinizes both the serum and the urine. Serum alkalinization keeps salicylates in their deprotonated (ionized) form, preventing them from crossing the blood-brain barrier and worsening central nervous system toxicity. Urine alkalinization traps the ionized salicylates in the renal tubules, significantly enhancing their renal excretion.

Step-by-Step Solution

Calculate the anion gap to identify the primary metabolic disturbance.

\text{AG} = 140 - (104 + 12) = 24 \text{ mEq/L}

, indicating a high anion gap metabolic acidosis.

An elevated anion gap is the first step in diagnosing the etiology of a metabolic acidosis.

Apply Winter's formula to determine the expected respiratory compensation.

\text{Expected PaCO}_2 = 1.5 \times 12 + 8 = 26 \pm 2 \text{ mm Hg}

This determines if the respiratory response is purely compensatory or if a secondary acid-base disorder is present.

Compare the actual

\text{PaCO}_2

to the expected

\text{PaCO}_2

The actual

\text{PaCO}_2

(

18 \text{ mm Hg}

) is significantly lower than the expected range (

24-28 \text{ mm Hg}

A lower than expected

\text{PaCO}_2

confirms the presence of a concomitant primary respiratory alkalosis.

Synthesize the mixed acid-base disorder with the clinical presentation.

The combination of tinnitus, fever, tachypnea, agitation, and a mixed high anion gap metabolic acidosis with primary respiratory alkalosis strongly indicates salicylate toxicity.

Recognizing this toxidrome is essential to avoid potentially fatal mismanagement.

Select the appropriate targeted therapy for salicylate toxicity.

Intravenous sodium bicarbonate is selected to alkalinize the blood and urine.

Alkalinization traps the salicylate ion in the renal tubules, enhancing excretion and reducing central nervous system toxicity.

Key Concept

Patients with acute salicylate toxicity present with a classic mixed acid-base disorder: a primary respiratory alkalosis (due to direct medullary stimulation) and a high anion gap metabolic acidosis (due to uncoupling of oxidative phosphorylation). Management centers on urine alkalinization with intravenous sodium bicarbonate.

Question 2537Question →

A $71$ -year-old man is evaluated on hospital day $3$ for ongoing management of acute pyelonephritis and concurrent bacteremia. At the time of admission, he presented with a temperature of $39.4^\circ\text{C}$ ( $102.9^\circ\text{F}$ ), heart rate of $112 \text{ /min}$ , and blood pressure of $88/54 \text{ mm Hg}$ . Following aggressive fluid resuscitation, he was empirically started on intravenous ceftriaxone. He has demonstrated significant clinical improvement, currently reporting minimal flank pain. Today, his temperature is $37.5^\circ\text{C}$ ( $99.5^\circ\text{F}$ ) and blood pressure is $122/78 \text{ mm Hg}$ . Blood and urine cultures obtained prior to antibiotic initiation both demonstrate heavy growth of *Enterobacter cloacae*. The microbiology laboratory reports the following minimum inhibitory concentrations (MIC) and interpretations for the isolate:

Antimicrobial Agent	Interpretation
Ampicillin	Resistant
Cefazolin	Resistant
Ceftriaxone	Susceptible
Cefepime	Susceptible
Piperacillin-tazobactam	Susceptible
Meropenem	Susceptible

Which of the following is the most appropriate next step in pharmacotherapy?

Switch to intravenous cefepime

Continue intravenous ceftriaxone

Switch to intravenous meropenem

Switch to intravenous piperacillin-tazobactam

Add oral clavulanate to the current regimen

Show answer & explanation

Answer: Switch to intravenous cefepime

Answer

The most appropriate next step is to switch to intravenous cefepime.

The correct approach involves recognizing that *Enterobacter cloacae* produces an inducible chromosomal AmpC beta-lactamase. Third-generation cephalosporins (like ceftriaxone) act as strong inducers of this enzyme and are subsequently hydrolyzed by it, leading to treatment failure even when in vitro testing reports them as susceptible. Cefepime, a fourth-generation cephalosporin, is uniquely stable against AmpC hydrolysis and is a very weak inducer of the enzyme. According to current infectious disease guidelines, cefepime is the definitive drug of choice for invasive AmpC-producing infections (like bacteremia) that are susceptible to it.

Step-by-Step Solution

Identify the pathogen's intrinsic resistance profile.

*Enterobacter cloacae* is recognized as a SPACE organism carrying an inducible chromosomal AmpC beta-lactamase gene.

Understanding the pathogen's resistance mechanisms is critical because in vitro susceptibility does not always predict in vivo efficacy.

Evaluate the current empiric therapy (ceftriaxone) against the pathogen's profile.

Although ceftriaxone tests as 'Susceptible' in vitro, it is a strong inducer of AmpC and is easily hydrolyzed by it.

Continuing a third-generation cephalosporin for an AmpC producer risks selecting for derepressed mutant strains, leading to inevitable clinical failure.

Select the optimal definitive therapy that balances efficacy and antimicrobial stewardship.

Cefepime is chosen over meropenem and piperacillin-tazobactam.

Cefepime (a fourth-generation cephalosporin) is highly stable against AmpC enzymes and is preferred over carbapenems to prevent the emergence of multi-drug resistant organisms.

Key Concept

Management of invasive infections caused by AmpC-producing Enterobacterales (e.g., *Enterobacter cloacae*) requires transitioning from third-generation cephalosporins to cefepime to prevent inducible resistance, even when in vitro testing suggests broader susceptibility.

Estimated Time:1m 30s

Question 2538Question →

A 61-year-old female is evaluated in the hospital on day 4 of admission for a non-healing right foot ulcer. She has a 15-year history of type 2 diabetes mellitus complicated by severe peripheral neuropathy. On admission, she presented with localized erythema, warmth, and purulent drainage from a deep plantar ulcer. A probe-to-bone test was positive. She was hemodynamically stable with no signs of systemic inflammatory response syndrome. A deep bone biopsy was obtained for culture, and she was empirically started on intravenous vancomycin and piperacillin-tazobactam.

Today, her erythema has significantly improved. She remains afebrile and hemodynamically stable. The bone biopsy culture results are now available, demonstrating heavy growth of two organisms. Blood cultures show no growth.

The antimicrobial susceptibility report is as follows:

Antimicrobial	Proteus mirabilis	Bacteroides fragilis
Ampicillin	Resistant	Not tested
Cefazolin	Resistant	Not tested
Ceftriaxone	Susceptible	Not tested
Ciprofloxacin	Resistant	Not tested
Clindamycin	Not tested	Resistant
Metronidazole	Not tested	Susceptible
Meropenem	Susceptible	Susceptible
Piperacillin-tazobactam	Susceptible	Susceptible

Based on these results, which of the following is the most appropriate next step in this patient's antimicrobial management?

Discontinue vancomycin and continue piperacillin-tazobactam.

Discontinue current antibiotics and initiate meropenem.

Discontinue current antibiotics and initiate ceftriaxone and metronidazole.

Continue the current empiric regimen of vancomycin and piperacillin-tazobactam.

Discontinue current antibiotics and initiate ciprofloxacin and metronidazole.

Show answer & explanation

Answer: Discontinue current antibiotics and initiate ceftriaxone and metronidazole.

Answer

Discontinue current antibiotics and initiate ceftriaxone and metronidazole.

The patient has diabetic foot osteomyelitis. Her bone culture grew Proteus mirabilis (a Gram-negative rod) and Bacteroides fragilis (an obligate anaerobe). Antimicrobial stewardship principles dictate that once culture and susceptibility data are available, broad-spectrum empiric therapy should be de-escalated to the narrowest-spectrum effective regimen. P. mirabilis is susceptible to ceftriaxone, which is a third-generation cephalosporin with a narrower spectrum than piperacillin-tazobactam or meropenem (it lacks anti-pseudomonal activity). B. fragilis is susceptible to metronidazole, a targeted anaerobic agent. Therefore, the combination of ceftriaxone and metronidazole provides optimal, targeted coverage for both isolated pathogens while minimizing collateral damage to the microbiome.

Step-by-Step Solution

Identify the clinical diagnosis and the organisms isolated.

The patient has diabetic foot osteomyelitis caused by Proteus mirabilis and Bacteroides fragilis.

A positive probe-to-bone test in a deep diabetic ulcer indicates osteomyelitis, which is confirmed by heavy growth on deep bone biopsy culture.

Analyze the antimicrobial susceptibility data for both organisms.

P. mirabilis is susceptible to ceftriaxone, meropenem, and piperacillin-tazobactam, but resistant to ampicillin, cefazolin, and ciprofloxacin. B. fragilis is susceptible to metronidazole, meropenem, and piperacillin-tazobactam.

Selecting an effective regimen requires matching the susceptibility profiles of all isolated pathogens.

Apply antimicrobial stewardship principles to select the optimal definitive therapy.

Ceftriaxone (for P. mirabilis) plus metronidazole (for B. fragilis) is selected.

This combination is the narrowest-spectrum regimen that effectively treats both organisms, avoiding the unnecessary use of anti-pseudomonal agents or carbapenems.

Key Concept

In patients with polymicrobial infections, empiric broad-spectrum antibiotics should be de-escalated to the narrowest-spectrum regimen effective against all isolated organisms to promote antimicrobial stewardship and prevent resistance.

Question 2539Question →

A 3-week-old full-term boy is brought to the pediatric outpatient clinic by his parents due to a new facial rash. The parents first noticed the lesions 4 days ago, and they have gradually increased in number. The infant is exclusively breastfed, feeds vigorously, and has appropriate wet and dirty diapers. Vital signs are within normal limits. Physical examination reveals multiple scattered inflammatory papules and pustules located on the cheeks, chin, and forehead. There are no open or closed comedones. The remainder of the skin examination is unremarkable. Which of the following is the most appropriate next step in management?

Obtaining a swab of the pustules for bacterial culture

Application of topical clotrimazole cream

Parental education and daily washing with mild soap

Initiation of oral cephalexin therapy

Prescription of topical hydrocortisone therapy

Show answer & explanation

Answer: Parental education and daily washing with mild soap

Answer

Parental education and daily washing with mild soap

The patient's presentation of inflammatory papules and pustules on the face at approximately 3 weeks of age, in the absence of comedones, is the classic description of neonatal cephalic pustulosis. Unlike infantile acne, which occurs later (usually 3-4 months) and features comedones, neonatal cephalic pustulosis is a common, benign, and transient condition. The pathophysiology is thought to involve an inflammatory reaction to Malassezia colonization. Because the condition is self-limited and the infant is otherwise well-appearing and feeding normally, the most appropriate management is reassurance, parental education, and routine gentle cleansing with water or mild soap.

Step-by-Step Solution

Analyze the clinical presentation to establish a diagnosis.

The patient is 3 weeks old with inflammatory facial papules and pustules lacking comedones, which is classic for neonatal cephalic pustulosis.

Accurate diagnosis of neonatal rashes prevents unnecessary workup and treatment.

Determine the appropriate management for the diagnosed condition.

Identify that the condition is benign and self-limiting, requiring only supportive care.

Avoiding over-treatment is a key principle in managing benign newborn findings.

Key Concept

Neonatal cephalic pustulosis is a benign, self-limiting condition presenting around 3 weeks of age with facial pustules lacking comedones, managed purely with supportive care and gentle cleansing.

Question 2540Question →

An 81-year-old man is brought to the emergency department from a skilled nursing facility due to sudden-onset severe respiratory distress that began 2 hours ago. The nursing facility staff reports that he has been coughing up pink, frothy sputum. His medical history includes hypertension, coronary artery disease, and severe chronic obstructive pulmonary disease. He is currently prescribed inhaled tiotropium, as-needed albuterol, aspirin, and metoprolol. Upon arrival, his temperature is 37.0°C (98.6°F), blood pressure is 172/98 mmHg, pulse is 114/min, and respirations are 28/min. Pulse oximetry is 86% on room air. Physical examination reveals an anxious patient sitting upright and using accessory muscles of respiration. Jugular venous pulsations are visible 6 cm above the sternal angle. Auscultation of the chest reveals diffuse bilateral crackles extending to the apices and scattered expiratory wheezing. Cardiac examination reveals a regular tachycardia and a distinct third heart sound. Bilateral lower extremity pitting edema is present. A point-of-care urinalysis shows positive leukocyte esterase, positive nitrites, and 20 white blood cells per high-power field. Which of the following is the most appropriate initial pharmacological management for this patient?

Intravenous bumetanide

Intravenous methylprednisolone

Nebulized ipratropium bromide

Intravenous piperacillin-tazobactam

Intravenous levofloxacin

Show answer & explanation

Answer: Intravenous bumetanide

Answer

Administration of a loop diuretic, such as intravenous bumetanide, is the most appropriate initial therapy.

The correct intervention focuses on rapid volume offloading. The patient's presentation—sudden severe dyspnea, hypertension, pink frothy sputum, JVD, bilateral crackles, and an S3 gallop—is the classic clinical picture of acute decompensated heart failure (ADHF) presenting as cardiogenic pulmonary edema. Intravenous loop diuretics (like bumetanide or furosemide) are the mainstay of initial pharmacological therapy because they rapidly reduce intravascular volume and venous return, alleviating pulmonary congestion.

Step-by-Step Solution

Analyze the patient's acute respiratory presentation and vital signs.

The patient has severe hypoxia, tachypnea, severe hypertension, and is coughing up pink, frothy sputum.

Identifying the acuity and characteristics of the respiratory failure helps narrow the differential diagnosis.

Evaluate the physical examination findings to differentiate the cause of dyspnea.

Elevated jugular venous pressure, bilateral crackles, an S3 gallop, and lower extremity edema strongly indicate volume overload and left ventricular failure.

Patients with a history of COPD can present with wheezing during heart failure exacerbations (cardiac asthma), but an S3 gallop and JVD are specific to a cardiogenic etiology.

Determine the significance of the abnormal urinalysis in the absence of fever or specific urinary symptoms.

The abnormal urinalysis in an elderly nursing home resident without systemic infectious signs likely represents asymptomatic bacteriuria.

Avoidance of unnecessary antibiotics (antibiotic stewardship) is critical unless the patient has a clear symptomatic infection.

Select the most appropriate initial management based on the primary diagnosis.

The primary issue is acute decompensated heart failure (ADHF); therefore, intravenous loop diuretics are the first-line pharmacological treatment.

Loop diuretics decrease fluid volume and venous return (preload), rapidly improving pulmonary congestion and oxygenation.

Key Concept

Patients with acute decompensated heart failure often present with sudden severe dyspnea, hypertension, an S3 gallop, and pulmonary crackles; initial management prioritizes preload reduction with intravenous loop diuretics.

PreviousPage 127 / 414Next

All practice questions

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution